Provided By GlobeNewswire
Last update: Jul 30, 2025
SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets.
Read more at globenewswire.comNASDAQ:ALGS (8/8/2025, 8:18:46 PM)
7.69
-0.44 (-5.41%)
Find more stocks in the Stock Screener